Accendra Health (ACH) is One of The 15 Best NYSE Penny Stocks According to Hedge Funds
Accendra Health Inc. (NYSE:ACH) said on June 23 it completed exchange offers for its 4.5% senior notes due 2029 and 6.625% senior notes due 2030. The notes were exchanged for new 9% senior secured first-lien notes due 2032 and 9.75% senior secured second-lien notes due 2033. Accendra expects to issue about $539.25 million first-lien notes and about $698.1 million second-lien notes, while S&P Global Ratings affirmed a 'B' issuer rating and moved outlook to stable.
How this was made
The 30-second read
Why it matters
The refinancing changes the maturity and lien structure of the company’s debt and is accompanied by S&P Global Ratings confirming the issuer rating and moving the outlook to stable, while still flagging short-term earnings strain and a loss of a large commercial contract.
Market read
Traders can reassess ACH’s credit risk and potential equity sensitivity to secured-debt recovery prospects and leverage/FOCF trajectory.
What to watch
Second-lien notes receive CCC+ with minimal recovery expectations, which can cap risk appetite even if first-lien recovery prospects are stronger.
Background
Accendra previously initiated exchange offers for its outstanding senior notes; the article states the final settlement and the resulting new secured note structure.
Ticker impact
Accendra Health disclosed exchange of its 4.5% 2029 and 6.625% 2030 notes into new 9% first-lien and 9.75% second-lien notes, plus S&P outlook change.
Moderate, two-sided reaction likely, with credit-spread sensitivity around leverage/FOCF targets.
The article provides concrete capital structure changes and a rating outlook shift, but it is framed as a settlement/exchange rather than a new operating catalyst.
Market effects
Highlights ongoing refinancing and credit-metric management risk in healthcare services, which can influence sector credit spreads.
Primarily US credit markets and NYSE small/mid-cap sentiment.
Limited direct global impact; mostly affects US high-yield/secured debt pricing.
Counterpoint
The stable outlook may not translate into equity upside if leverage remains elevated and FOCF-to-debt targets are still stressed by separation and acquisition costs.
Key entities
- issuerAccendra Health Inc.
NYSE-listed healthcare solutions provider whose senior notes were exchanged into new secured first- and second-lien notes.
- rating_agencyS&P Global Ratings
Confirmed the 'B' issuer rating and changed outlook from negative to stable; assigned CCC+ to second-lien and B+ to first-lien notes.
